Stockscreener 앱 받기
64.30
1.55%
-1.06
Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스
Why is Halozyme Therapeutics (HALO) down 13.1% since last earnings report? - MSN
Halozyme raises outlook, buys Surf Bio - MSN
Halozyme granted injunction in Germany barring Merck's subcutaneous Keytruda - MSN
Vertex Pharma in pact with Halozyme for Hypercon drug delivery tech - MSN
Halozyme Therapeutics Inc (HAM:RV7) Stock Price & 30 Year Financial Data - GuruFocus
Why Is Halozyme Therapeutics (HALO) Down 2.2% Since Last Earnings Report? - MSN
Halozyme Therapeutics prices $1.3 billion convertible notes - MSN
Halozyme Therapeutics Inc. (HALO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Halozyme Therapeutics updates bylaws on director removal and stockholder meetings By Investing.com - Investing.com South Africa
Halozyme Therapeutics updates bylaws on director removal and stockholder meetings - Investing.com
Halozyme (NASDAQ: HALO) board revises bylaws on director removal, meetings - Stock Titan
Asset Management One Co. Ltd. Increases Stock Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
HALO Price Today: Halozyme Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Is It Too Late To Consider Halozyme Therapeutics (HALO) After Its Recent Share Price Rebound - Sahm
HALO (Halozyme Therapeutics) rises 0.95 percent as Q4 2025 37.5 percent revenue growth offsets steep EPS miss. - Xã Thanh Hà
HALO Stock Price, Quote & Chart | HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - ChartMill
HALO (Halozyme Therapeutics) edges up 0.4 percent after Q4 2025 results, with 37.5 percent revenue growth offsetting steep EPS miss.Gamma Squeeze - Cổng thông tin điện tử tỉnh Lào Cai
Halozyme Therapeutics (HALO) Stock: Risk Factors (Investor Interest) 2026-04-22Expert Verified Trades - Cổng thông tin điện tử Tỉnh Sơn La
Boston Trust Walden Corp Sells 52,058 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Choreo LLC Sells 28,448 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Is Halozyme Therapeutics (HALO) Offering Value After Mixed Multi Year Share Price Performance - Yahoo Finance
Goldman Sachs Maintains Halozyme Therapeutics (HALO) Neutral Recommendation - MSN
Halozyme Therapeutics, Inc. Experiences Revision in Its Stock Evaluation Amid Mixed Performance Metrics - Markets Mojo
Morgan Stanley Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Raises Target Price to $96 - Moomoo
(HALO) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Halozyme Therapeutics Partners with Vertex for Hypercon Technology - HarianBasis.co
Is Halozyme Therapeutics (HALO) stock reacting to risk factors (+0.06%) 2026-04-20Certified Trade Ideas - Cổng thông tin điện tử Tỉnh Sơn La
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Unpacking the 22.67% Potential Upside - DirectorsTalk Interviews
Assessing Halozyme Therapeutics (HALO) Valuation After Recent Share Price Strength Without Major News - Sahm
Is Halozyme Therapeutics (HALO) One of the Most Undervalued Biotech Stocks to Buy Right Now? - Insider Monkey
Lobbying Update: $70,000 of HALOZYME THERAPEUTICS INC. lobbying was just disclosed - Quiver Quantitative
Halozyme Therapeutics Inc at Leerink Global Healthcare Conference Transcript - GuruFocus
8 Most Undervalued Biotech Stocks to Buy Right Now - Insider Monkey
Assetmark Inc. Has $9.25 Million Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (HALO) to Report Q4 Results: Wall Street Expects Earnings Growth - Eastern Progress
Halozyme Therapeutics, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
CapEx per share of Halozyme Therapeutics, Inc. – BX:RV7 - TradingView — Track All Markets
Working capital per share of Halozyme Therapeutics, Inc. – BX:RV7 - TradingView — Track All Markets
Halozyme Therapeutics (HALO) appoints interim CFO amid growth plans - MSN
TD Cowen reiterates Halozyme stock Buy rating on royalty growth By Investing.com - Investing.com Canada
Paragon Capital Boosts Stake in Halozyme Therapeutics - National Today
Paragon Capital Management Inc. Purchases New Shares in Halozyme Therapeutics, Inc. $HALO - MarketBeat
A Look At Halozyme Therapeutics (HALO) Valuation After New Vertex Collaboration And Licensing Deal - Sahm
Halozyme Therapeutics Inc (HAM:RV7) Dividend - GuruFocus
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: A Biotech Powerhouse with 25% Upside Potential - DirectorsTalk Interviews
Halozyme Vertex Hypercon Deal Opens New Royalty And Growth Pathways - Sahm
HALO (Halozyme Therapeutics) Dividends Paid - GuruFocus
HALO (Halozyme Therapeutics) Unearned Premiums - GuruFocus
Did Halozyme’s Vertex Hypercon Licensing Deal Just Shift Halozyme Therapeutics’ (HALO) Investment Narrative? - Yahoo Finance
Liquidity Mapping Around (HALO) Price Events - Stock Traders Daily
Halozyme (HALO) loses 9% on weak earnings - MSN
Halozyme Therapeutics, Inc.Common Stock (NQ: HALO - FinancialContent
1.73%
2.52%
자본화:
|
볼륨(24시간):